In this study, we verified the hypothesis that the metabolic stress sensor TRIB3 collaborates with the oncoprotein PML-RARα to inhibit PPARγ activity and subsequently cause dyslipidemia in newly diagnosed APL patients. Here, PPARG is linked to metabolic syndrome.